| Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting A Slomp, LM Moesbergen, J Gong, M Cuenca, PA von dem Borne, ... Blood Advances 3 (24), 4202-4214, 2019 | 79 | 2019 |
| Regulatory roles of IL-10–producing human follicular T cells PF Cañete, RA Sweet, P Gonzalez-Figueroa, I Papa, N Ohkura, H Bolton, ... Journal of Experimental Medicine 216 (8), 1843-1856, 2019 | 64 | 2019 |
| CD Maps–dynamic profiling of CD1 to CD100 surface expression on human leukocyte and lymphocyte subsets T Kalina, K Fiser, M Pérez-Andrés, D Kuzílková, M Cuenca, SJW Bartol, ... Frontiers in immunology 10, 2434, 2019 | 61 | 2019 |
| Cutting edge: Ly9 (CD229), a SLAM family receptor, negatively regulates the development of thymic innate memory-like CD8+ T and invariant NKT cells J Sintes, M Cuenca, X Romero, R Bastos, C Terhorst, A Angulo, P Engel The Journal of Immunology 190 (1), 21-26, 2013 | 42 | 2013 |
| Ly9 (CD229) cell-surface receptor is crucial for the development of spontaneous autoantibody production to nuclear antigens J de Salort, M Cuenca, C Terhorst, P Engel, X Romero Frontiers in immunology 4, 225, 2013 | 38 | 2013 |
| CD84 cell surface signaling molecule: An emerging biomarker and target for cancer and autoimmune disorders M Cuenca, J Sintes, A Lanyi, P Engel Clinical Immunology 204, 43-49, 2019 | 28 | 2019 |
| Endochondral Bone Regeneration by Non-Autologous Mesenchymal Stem Cells A Longoni, I Pennings, M Cuenca, MHP Van Rijen, V Peperzak, ... Frontiers in Bioengineering and Biotechnology 8, 651, 2020 | 20 | 2020 |
| Targeting of Ly9 (CD229) Disrupts Marginal Zone and B1 B Cell Homeostasis and Antibody Responses M Cuenca, X Romero, J Sintes, C Terhorst, P Engel The Journal of Immunology 196 (2), 726-737, 2016 | 20 | 2016 |
| Ly9 (SLAMF3) receptor differentially regulates iNKT cell development and activation in mice M Cuenca, J Puñet‐Ortiz, M Ruart, C Terhorst, P Engel European journal of immunology 48 (1), 99-105, 2018 | 9 | 2018 |
| Ly9 (CD229) antibody targeting depletes marginal zone and germinal center B cells in lymphoid tissues and reduces salivary gland inflammation in a mouse model of Sjögren’s Syndrome J Puñet-Ortiz, M Sáez Moya, M Cuenca, EJ Caleiras, A Lazaro, P Engel Frontiers in immunology 9, 2661, 2018 | 8 | 2018 |
| Viral CD229 (Ly9) homologs as new manipulators of host immunity A Angulo, M Cuenca, P Martínez‐Vicente, P Engel Journal of leukocyte biology 105 (5), 947-954, 2019 | 7 | 2019 |
| Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma I Spaan, LM Timmerman, T Kimman, A Slomp, M Cuenca, ... Blood Advances 5 (12), 2593-2607, 2021 | 5 | 2021 |
| The checkpoint regulator SLAMF3 preferentially prevents expansion of auto-reactive B cells generated by graft-vs.-host disease N Wang, B Yigit, CE van der Poel, M Cuenca, MC Carroll, RW Herzog, ... Frontiers in immunology 10, 831, 2019 | 5 | 2019 |
| Advances and Perspectives in the Treatment of B-Cell Malignancies M Cuenca, V Peperzak Cancers 13 (9), 2266, 2021 | 4 | 2021 |
| Targeting B-cell maturation antigen increases sensitivity of multiple myeloma cells to MCL-1 inhibition M Cuenca, N Van Nieuwenhuijzen, LM Moesbergen, A Bloem, ... Haematologica, 2020 | 3 | 2020 |
| In Vitro Model to Predict Response to Daratumumab Therapy in Relapsed/Refractory Multiple Myeloma N Van Nieuwenhuijzen, M Cuenca, L Abbink, E Lammers, M Jak, ... Blood 138, 1568, 2021 | 1 | 2021 |
| CD38 and CD45 expression on plasma cells and response to daratumumab in Multiple Myeloma E Lammers, M Cuenca, A Bloem, M Minnema, M Jak Clinical Lymphoma, Myeloma and Leukemia 19 (10), e164, 2019 | 1 | 2019 |
| CD Maps-Dynamic Profiling of CD1 to CD100 Surface Expression on Human Leukocyte and Lymphocyte Subsets K Fišer, T Kalina, M Perez-Andres, D Kužílková, P Engel, M Cuenca, ... Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …, 2019 | | 2019 |
| Multiple myeloma with amplification of chromosome 1q is highly sensitive to MCL-1 targeting A Slomp, L Moesbergen, J Gong, M Cuenca, P von dem Borne, ... Clinical Lymphoma, Myeloma and Leukemia 19 (10), e49-e50, 2019 | | 2019 |
| Dexamethasone synergizes with MCL-1 inhibition in multiple myeloma through suppression of S6 phosphorylation I Spaan, L Timmerman, T Kimman, A Slomp, M Cuenca, M Minnema, ... Clinical Lymphoma, Myeloma and Leukemia 19 (10), e110, 2019 | | 2019 |
